Trial Profile
Effects of natalizumab on microRNA-126 expression in patients with multiple sclerosis (MS) compared with untreated patients with MS and healthy volunteers
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 30 Oct 2018
Price :
$35
*
At a glance
- Drugs Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Biomarker; Pharmacodynamics; Pharmacogenomic
- 12 Oct 2018 Results presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
- 10 Nov 2015 New trial record